我国原发性肝癌筛查的现状、挑战及发展方向

doi:10.16150/j.1671-2870.2024.01.002

摘要/Abstract

摘要：

2020年，全球原发性肝癌是第6位最常见的恶性肿瘤，全球新诊断病例90.57万，而由原发性肝癌导致的死亡率高居恶性肿瘤致死第3位，合计约83万，总体死亡率为8.7/10万。2020年，亚洲地区新增原发性肝癌65.7万例，死亡60.9万例，分别占全球的72.5%、73.3%。2020年，我国新增原发性肝癌患者41万例，死亡39.1万例，死亡率为17.2/10万，高居恶性肿瘤致死的第2位。全球每年近半数的原发性肝癌新发病例及死亡病例发生在我国，疾病负担沉重。肝细胞癌（hepatocellular carcinoma， HCC）占原发性肝癌的75%~85%。我国的HCC患者由于确诊时大多处于中晚期，年龄标化的5年生存率仅为14.1%，预后极差。HCC早诊率低是导致患者治疗效果差的重要原因之一，而提高HCC早诊率的关键在于进行有效的HCC筛查。传统的“腹部超声+血甲胎蛋白检测”的筛查手段，远不能满足临床筛查早期HCC的需求，存在筛查执行率低、对早期HCC筛查的灵敏度低、肝癌基础病因变化对HCC筛查形成了新的挑战等问题。为优化HCC筛查效果、改善患者预后，应对策略需从患者及医护等多角度入手提高HCC筛查的执行率，开发准确率更高、便捷性更好的新型HCC筛查手段[如GALAD（gender, age, AFP-L3, DCP, AFP）评分、液体活检等]，提倡“个体化”筛查的策略，分层富集和精准筛查，优化医疗资源使用的成本效益比。作为个体化筛查策略之一的“数字化”赋能闭环肝病精细化管理及HCC筛查是创新模式，也是我国管理应对策略的选择之一。

关键词: 肝癌, 筛查, 早期诊断, 挑战, 应对策略

Abstract:

In 2020, primary liver cancer ranked as the sixth most common malignancy worldwide, with 905 700 newly-diagnosed cases, and 830 000 deaths with an overall mortality rate of 8.7/100 000, ranking third in in malignant tumors. In Asia, there were 657 000 newly-diagnosed cases and 609 000 deaths, accounting for 72.5% and 73.3% of the global burden, respectively. In China, primary liver cancer is one of the most common malignant tumors, with 410 000 new cases, and 391000 deaths with a mortality rate of 17.2/100 000, ranking the second highest among the causes of cancer deaths. Approximately half of annual global newly-diagnosed cases and deaths of liver cancer occurred in China, leading to an extremely heavy disease burden. Hepatocellular carcinoma (HCC) accounts for 75%-85% of primary liver cancer. The 5-year survival rate of HCC patients is merely 14.1% in China, mainly due to advanced disease stage at the diagnosis in most HCC patients. The low rate of diagnosis of early-stage HCC is one of the most important reasons for the poor treatment outcome of HCC patients. The key to improving the diagnosis of early-stage HCC lies on the effective HCC surveillance. The current surveillance method of “abdominal ultrasound + alpha-fetoprotein” is far from meeting the clinical needs in detecting early-stage HCC, which is faced with many problems, including low implementation rates of HCC screening, poor sensitivity for early-stage HCC, and new challenges posed by profound changes in the underlying etiologies of hepatocellular carcinoma in the past decade. In order to optimize the efficacy of HCC surveillance and improve the prognosis of HCC patients, we must adopt effective strategies, raise the implementation rate of HCC surveillance from the perspectives of patients and healthcare professionals, develope new HCC surveillance tools of higher accuracy and with more convenience, [GALAD(gender, age, AFP-L3, DCP, AFP) score and liquid biopsy]; advocating “individualized” surveillance strategies, stratified enrichment and precise screening to maximize the cost-effectiveness of healthcare resources. As one innovative model for individualized HCC surveillance, “artificial intelligence” in closed-loop precise liver disease management may serve as a strategic choice for disease management in China.

Key words: Hepatocellular carcinoma, Surveillance, Early detection, Challenges, Coping strategies

中图分类号:

姜绍文, 周惠娟, 谢青. 我国原发性肝癌筛查的现状、挑战及发展方向[J]. 诊断学理论与实践, 2024, 23(01): 9-15.

JIANG Shaowen, ZHOU Huijuan, XIE Qing. Current status, challenges and future directions for hepatocellular carcinoma surveillance in China[J]. Journal of Diagnostics Concepts & Practice, 2024, 23(01): 9-15.

参考文献 29

[1]	国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2):288-303.
	General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2):288-303.
[2]	SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[3]	姜绍文, 谢青. 液体活检在肝细胞肝癌早期筛查中的作用及研究进展[J]. 临床内科杂志, 2022, 39(12):802-806.
	JANG S W, XIE Q. Role of liquid biopsy in early scree-ning of hepatocellular carcinoma and its relevant research progress[J]. J Clin Intern Med, 2022, 39(12):802-806.
[4]	中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版)[J]. 临床肝胆病杂志, 2021, 37(3):532-542.
	Chinese Society of Hepatology, Chinese Medical Association. Consensus on the secondary prevention for primary liver cancer (2021 edition)[J]. J Clin Hepatol, 2021, 37(3):532-542.
[5]	HUANG D Q, SINGAL A G, KANWAL F, et al. Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(12):797-809. doi: 10.1038/s41575-023-00818-8 pmid: 37537332
[6]	International Agency for Research on Cancer,World Health Organization. Liver Source: Globocan 2020[EB/OL]. [2023-12-25]. https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf
[7]	中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国研究型医院学会肝病专业委员会, 中华医学会肝病学分会, 等. 原发性肝癌的分层筛查与监测指南(2020版)[J]. 中华肝脏病杂志, 2021, 29(1):25-40.
	The Prevention and Control Professional Committee of Hepatobiliary Pancreatic Diseases of the Chinese Association of Preventive Medicine, The Liver Disease Professional Committee of the Chinese Research Hospital Association. et al. The Hepatology Branch of the Chinese Medical Association,Guideline for stratified screening and surveillance of primary liver cancer(2020 Edition)[J]. Chin J Hepatol, 2021, 29(1):25-40.
[8]	PARK J W, CHEN M, COLOMBO M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35(9):2155-2166.
[9]	MARRERO J A, KULIK L M, SIRLIN C B, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2):723-750. doi: 10.1002/hep.29913 pmid: 29624699
[10]	WOLF E, RICH N E, MARRERO J A, et al. Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis[J]. Hepatology, 2021, 73(2):713-725.
[11]	ZHAO C, JIN M, LE R H, et al. Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue[J]. Liver Int, 2018, 38(3):503-514. doi: 10.1111/liv.13555 pmid: 28834146
[12]	JUN D W, CHO Y K, SOHN J H, et al. A study of the awareness of chronic liver diseases among Korean adults[J]. Korean J Hepatol, 2011, 17(2):99-105.
[13]	Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study[J]. Lancet Gastroenterol Hepatol, 2023, 8(10):879-907.
[14]	WALKER M, EL-SERAG H B, SADA Y, et al. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer[J]. Aliment Pharmacol Ther, 2016, 43(5):621-630.
[15]	ALEXANDER M, LOOMIS A K, FAIRBURN-BEECH J, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease[J]. BMC Med, 2018, 16(1):130. doi: 10.1186/s12916-018-1103-x pmid: 30099968
[16]	SIMMONS O L, FENG Y, PARIKH N D, et al. Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance[J]. Clin Gastroenterol Hepatol, 2019, 17(4):766-773.
[17]	TZARTZEVA K, OBI J, RICH N E, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis[J]. Gastroenterology, 2018, 154(6):1706-1718. doi: S0016-5085(18)30155-0 pmid: 29425931
[18]	BRUIX J, SHERMAN M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3):1020-1022. doi: 10.1002/hep.24199 pmid: 21374666
[19]	FETZER D T, BROWNING T, XI Y, et al. Associations of Ultrasound LI-RADS Visualization Score With Examination, Sonographer, and Radiologist Factors: Retrospective Assessment in Over 10,000 Examinations[J]. Am J Roentgenol, 2022, 218(6):1010-1020.
[20]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. doi: S0168-8278(18)30215-0 pmid: 29628281
[21]	HUANG D Q, SINGAL A G, KONO Y, et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer[J]. Cell Metab, 2022, 34(7):969-977. doi: 10.1016/j.cmet.2022.05.003 pmid: 35793659
[22]	KENNEDY N A, RODGERS A, ALTUS R, et al. Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study[J]. Intern Med J, 2013, 43(7):772-777. doi: 10.1111/imj.12166 pmid: 23611607
[23]	SINGAL A G, REDDY S, RADADIYA AKA PATEL H, et al. Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance[J]. Clin Gastroenterol Hepatol, 2022, 20(12):2818-2825.
[24]	DEL POGGIO P, OLMI S, CICCARESE F, et al. A trai-ning program for primary care physicians improves the effectiveness of ultrasound surveillance of hepatocellular carcinoma[J]. Eur J Gastroenterol Hepatol, 2015, 27(9):1103-1108.
[25]	BESTE L A, IOANNOU G N, YANG Y, et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder[J]. Clin Gastroenterol Hepatol, 2015, 13(1):172-179.
[26]	ABERRA F B, ESSENMACHER M, FISHER N, et al. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis[J]. Dig Dis Sci, 2013, 58(4):1157-1160.
[27]	CHEN L, ABOU-ALFA G K, ZHENG B, et al. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients[J]. Cell Res, 2021, 31(5):589-592. doi: 10.1038/s41422-020-00457-7 pmid: 33589745
[28]	全国多中心前瞻性肝癌极早期预警筛查项目(PRECAR)专家组. 中国肝癌早筛策略专家共识[J]. 肝脏, 2021, 26(8):825-831.
	Expert Group on the National Multi center Prospective Early Warning and Screening Project for Liver Cancer (PRECAR). Expert consensus on early screening strategies for liver cancer in China[J]. Chin Hepatol, 2021, 26(8):825-831.
[29]	饶建华, 朱新华, 张弘炜, 等. 多纳非尼辅助治疗肝癌术后合并高危复发风险患者短期疗效和安全性的多中心回顾性研究[J]. 中华消化外科杂志, 2023, 22(12):1433-1443.
	RAO J H, ZHU X H, ZHANG H W, et al. Short-term efficacy and safety of Donafenib as postoperative adjuvant therapy for patients with high risk of recurrence after radical resection of hepatocellular carcinoma: a multicenter retrospective study[J]. Chin J Dig Surg, 2023, 22(12):1433-1443.